Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 1Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Glioblastoma 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 2Filgrastim 2Everolimus 2trifluridine tipiracil drug combination 1sargramostim 1poly ICLC 1pegfilgrastim 1pasireotide 1gadobutrol 1gadobenic acid 1dactolisib 1antineoplaston AS 2-1 1antineoplaston A10 1Yoga 1Vaccines 1Topotecan 1Surgical Procedures, Operative 1Radiotherapy 1O(6)-benzylguanine 1Methylphenidate 1Magnetic Resonance Spectroscopy 1Genistein 1Gadolinium DTPA 1Decitabine 1Cyclophosphamide 1Congresses as Topic 1Carmustine 12-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neuroectodermal Tumors, Primitive × dactolisib × Clear all
NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡